Survodutide vs Thymosin Alpha-1
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideImmune SupportAnti-Aging & Longevity
Thymosin Alpha-1- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
- Half-Life
- ~7 days
- 2–3 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 0.8–1.6 mg
- Frequency
- Once weekly
- Twice weekly
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Enhances T-cell and NK cell activity
- Supports recovery from viral and bacterial infections
- May reduce inflammation systemically
- Supports healthy aging and immune resilience
- Improves vaccine response
- Supports liver health
- May help with chronic fatigue syndrome and post-viral conditions
- Approved in multiple countries for hepatitis B and C treatment
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Injection site irritation
- Mild flu-like symptoms initially (immune activation)
- Fatigue (rare)
- Stacks With
- —
- —